Insider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells 55,615 Shares of Stock

Organogenesis Holdings Inc. (NASDAQ:ORGOGet Free Report) CEO Gary S. Gillheeney sold 55,615 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the sale, the chief executive officer now directly owns 3,044,779 shares of the company’s stock, valued at $10,230,457.44. This represents a 1.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Organogenesis Stock Down 9.2 %

ORGO opened at $3.24 on Thursday. The firm has a market cap of $429.55 million, a P/E ratio of -54.00 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business has a 50 day moving average price of $3.45 and a 200 day moving average price of $3.01. Organogenesis Holdings Inc. has a twelve month low of $2.16 and a twelve month high of $4.70.

Organogenesis (NASDAQ:ORGOGet Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period in the previous year, the company earned $0.02 earnings per share. Research analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its position in shares of Organogenesis by 251.7% during the 3rd quarter. Barclays PLC now owns 94,809 shares of the company’s stock worth $271,000 after purchasing an additional 67,855 shares during the last quarter. Wellington Management Group LLP increased its position in Organogenesis by 8.0% in the 3rd quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after buying an additional 17,842 shares during the period. State Street Corp lifted its holdings in shares of Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after buying an additional 9,090 shares during the last quarter. Verition Fund Management LLC boosted its position in shares of Organogenesis by 542.8% in the third quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock valued at $225,000 after acquiring an additional 66,448 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in shares of Organogenesis in the third quarter worth $36,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

(Get Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

Further Reading

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.